Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns

The drug, pociredir, was being developed as an ​oral treatment for sickle-cell disease, an inherited blood disorder that can cause ​pain, anemia, organ damage and reduced life expectancy.

Bengaluru: Fulcrum Therapeutics  said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viable regulatory path for the treatment.